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Cardiac Troponin I Levels Measured With a
High-Sensitive Assay Increase Over Time and
Are Strong Predictors of Mortality in an Elderly Population
Kai M. Eggers, MD, PHD,* Per Venge, MD, PHD,* Bertil Lindahl, MD, PHD,† Lars Lind, MD, PHD*
Uppsala, Sweden
Objectives This study sought to assess changes in troponin levels, underlying conditions, and the prognostic implications in
elderly subjects from the community.
Background Cardiac troponin levels are often detectable in community dwellers when sensitive assays are applied. However,
information on the course of troponin levels over time is limited.
Methods Cardiac troponin I (cTnI) was measured by using a novel, high-sensitive assay in community dwellers aged 70
years from the Prospective Investigation of the Vasculature in Uppsala Seniors study. Measurements were per-
formed at baseline (n  1,004) and after 5 years (n  814). Total follow-up was 8.0 years.
Results cTnI levels were detectable in 968 (96.4%) subjects at baseline and independently predicted all-cause mortality
(adjusted hazard ratio [HR]: 1.44 [95% confidence interval (CI): 1.18 to 1.77]) and cardiovascular mortality (ad-
justed HR: 1.66 [95% CI: 1.20 to 2.29]) when levels from baseline and 5-year follow-up were used as updated
covariates. The integrated discrimination improvement of cTnI regarding all-cause mortality was 0.014 (p 
0.04), and the category-free net reclassification improvement was 0.231 (p  0.02). Median cTnI levels in-
creased by 45% between both measurements. The change in cTnI levels was significantly related to male sex
(p  0.02), body mass index (p  0.01), high-density lipoprotein cholesterol (p  0.005), N-terminal pro–B-type
natriuretic peptide (p  0.004), and left ventricular ejection fraction (p  0.04), and it independently predicted
all-cause mortality occurring after 5-year follow-up (adjusted HR: 1.97 [95% CI: 1.14 to 3.40]; p  0.02).
Conclusions Using a novel high-sensitive assay, cTnI levels could be determined in nearly all elderly study subjects. cTnI levels
increased over time and were a strong marker of mortality risk. Our data suggest that cTnI might offer utility for
clinical assessment of subjects in the general population. (J Am Coll Cardiol 2013;61:1906–13) © 2013 by
the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.048The perception of what cardiac troponin stands for has
undergone a remarkable shift during the past decade, from
a biomarker believed to be synonymous with myocardial
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2012, accepted December 9, 2012.infarction to a general indicator of cardiomyocyte damage in
various clinical settings. Following the implementation of
high-sensitive assays, it has become clear that troponin
levels also may be elevated in community dwellers (1–5).
See page 1914
Troponin leakage in these populations is mainly associated
with chronic cardiac affections (e.g., left ventricular hyper-
trophy, impaired left ventricular systolic function and/or
myocardial ischemia due to stable coronary artery disease)
(1– 4). Similarly, cardiac troponins have been shown to be
strong predictors of adverse outcome in the community,
in particular with respect to mortality and incident heart
failure (2– 6).
Most studies evaluating general populations assessed
cardiac troponin T (2–5), whereas data on cardiac troponin I
(cTnI) are limited (1,6). In addition, even with the recent
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assessed populations had undetectable levels (2–5), which
limits available evidence regarding the true distribution of
troponin concentrations, their course over time, and the
underlying conditions and prognostic implications of
changes. To investigate these important issues closer, we
studied a fairly large sample of elderly community dwellers
participating in the PIVUS (Prospective Investigation of the
Vasculature in Uppsala Seniors) study in whom cTnI had
been measured by using a novel sensitive assay at both 70
and 75 years of age.
Methods
Study design. All individuals aged 70 years living in
Uppsala, Sweden, were eligible for participation in the
PIVUS study. Potential study participants were randomly
chosen from the registry of community inhabitants. Of the
2,025 individuals invited, a total of 1,016 participated in the
study with baseline investigations starting in April 2001 (7).
Follow-up was scheduled 5 years after enrollment, and 826
subjects (85.7% of all survivors) attended. Written informed
consent was obtained from all participants. The study
protocol was approved by the local ethics committee and
complied with the principles of the Declaration of Helsinki.
Laboratory analysis. cTnI was analyzed in frozen ethylenedi-
aminetetraacetic acid plasma samples on an ARCHITECT
i2000SR platform by using the ARCHITECT STAT hsTnI
assay (Abbott Laboratories, Abbott Park, Illinois). This
method is a double chemiluminescent immunoassay using a
capture antibody directed against amino acids 2440 of the
cTnI protein and a chimeric detection antibody directed
against amino acids 4147. The limits of blank and of
detection of this assay have been described as 0.9 and 1.5,
respectively, and the 99th percentile among healthy subjects
has been reported in the range of 13.6 to 23.0 ng/l (8,9).
The imprecision profile of 250 duplicate samples in our
internal validation showed a 10% coefficient of variation at
12.0 ng/l and a 20% coefficient of variation at 2.0 ng/l.
N-terminal pro–B-type natriuretic peptide (NT-proBNP)
was measured by using the Elecsys proBNP sandwich
immunoassay on an Elecsys 2010 instrument (Roche Diag-
nostics, Mannheim, Germany) and C-reactive protein on an
ARCHITECT ci8200 analyzer (Abbott Laboratories). The
estimated glomerular filtration rate (eGFR) was calculated
according to the 4-variable Modification of Diet in Renal
Disease Study equation (10).
Echocardiography. Echocardiography was performed with
an Acuson XP124 cardiac ultrasound unit (Siemens Medi-
cal Solutions, Malvern, Pennsylvania), as described previ-
ously (11). Left ventricular volumes were determined ac-
cording to the Teichholz method, and from those results,
left ventricular ejection fraction (LVEF) was determined.
Left ventricular mass index (LVMI) was calculated accord-
ing to the recommendations of the American Society of
Echocardiography (12).Prognostic evaluation. The
primary outcome examined in
the present analysis was all-cause
mortality based on data obtained
from the Swedish Registry on
Mortality and the medical re-
cords for Uppsala County. In
secondary analyses, we assessed
the association of cTnI with car-
diovascular mortality, defined as
death resulting from myocardial
infarction, stroke, heart failure,
other documented cardiovascular
diseases, sudden death, and
death not clearly attributable to
noncardiovascular disease. Two
follow-up periods were consid-
ered: from the baseline investiga-
tions until censor date at the end
of December 2010 and from
5-year follow-up until censor
date. This time frame enabled us
to investigate the prognostic im-
plications of changes in cTnI levels.
Statistical analysis. Continuous variables are described as
medians (with 25th and 75th percentiles) or mean  SD.
Between-group comparisons of continuous variables were
performed by using the Mann-Whitney U test or the 1-way
analysis of variance, as appropriate. The Wilcoxon signed
rank test was used for within-group comparisons of contin-
uous variables. Correlations between continuous variables
are described by using Spearman rank correlation coeffi-
cients. Categorical variables are expressed as frequencies and
percentages; differences were analyzed with the chi-square
test.
Independent predictors of baseline cTnI levels were
identified by multiple linear regressions. Tested covariates
included sex, hypertension (defined as blood pressure
140/90 mm Hg at rest or antihypertensive treatment),
diabetes (defined as fasting blood glucose 6.1 mmol/l or
antidiabetic treatment [including diet]), high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, current smoking, previous smoking, body mass
index, ischemic electrocardiographic changes (defined as
ST-segment depression [Minnesota codes 4-1 and 4-2],
T-wave inversion [Minnesota codes 5-1, 5-2, or 5-3],
pathologic Q-waves [Minnesota code 1-1], or left bundle
branch block [Minnesota code 7-1] on a conventional
12-lead electrocardiogram [13]), previous myocardial in-
farction, self-reported heart failure, previous coronary revas-
cularization, previous stroke, NT-proBNP, C-reactive pro-
tein, eGFR, LVEF, and LVMI. If necessary, continuous
variables were ln-transformed to achieve a normal distribu-
tion. The adjusted models included all covariates with a
Abbreviations
and Acronyms
CI  confidence interval
cTnI  cardiac troponin I
eGFR  estimated
glomerular filtration rate
HDL  high-density
lipoprotein
HR  hazard ratio
IDI  integrated
discrimination improvement
LDL  low-density
lipoprotein
LVEF  left-ventricular
ejection fraction
LVMI  left-ventricular
mass index
NRI  net reclassification
improvement
NT-proBNP  N-terminal
pro–B-type natriuretic
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defined as the absolute change between ln-transformed
levels over time. This criterion was chosen because changes
defined by this function approximated a normal distribution
(Shapiro-Wilk test statistic W: 0.90) to a greater extent
than other relative or absolute change criteria. Independent
predictors of changes were identified by multiple linear
regression models using the same set of covariates as for the
other multiple linear regressions, including cTnI (ln) at
baseline and intercurrent cardiovascular events (defined as
myocardial infarction, stroke, or coronary revascularization
occurring between the examinations at baseline and 5-year
follow-up). In an extended model, we also included the
changes in levels of NT-proBNP and the eGFR from 70 to
75 years of age (defined as the absolute change of
ln-transformed results between both measurements) as
covariates.
The prognostic value of ln-transformed cTnI levels was
investigated by using Cox proportional hazards regression
analysis adjusting for established cardiovascular risk indica-
tors: sex, hypertension, diabetes, HDL cholesterol, LDL
cholesterol, current smoking, body mass index, the eGFR
(ln), C-reactive protein (ln), and previous cardiovascular
disease (defined as a history of myocardial infarction, stroke,
or coronary revascularization). Additional adjustments were
made for NT-proBNP (ln) or alternatively for the LVEF
and LVMI. In secondary analyses, we investigated the
prognostic value of cTnI relative to the Framingham risk
score (14). In these models, we included cTnI levels (ln)
obtained at baseline and 5-year follow-up as updated
covariates to increase the number of observations.
We also investigated the prognostic implications of the
change in cTnI levels during the first 5 years regarding the
mortality risk until censor date at the end of December
2010. We used separate models adjusting either for estab-
lished cardiovascular risk indicators or the Framingham risk
score. Both models were additionally adjusted for cTnI (ln)
at baseline and intercurrent cardiovascular events between
70 and 75 years of age.
Kaplan-Meier curves were constructed to illustrate the
timing of events. The shape of the relationship between
baseline cTnI levels and mortality risk was evaluated by
using a generalized additive model (2 df). The incremental
prognostic value of cTnI was investigated by calculating the
C-statistic with comparison of differences using the method
described by DeLong et al. (15), as well as estimation of the
integrated discrimination improvement (IDI) and of the net
reclassification improvement (NRI) as described by Pencina
et al. (16,17). We assessed both the category-free NRI and
the category-based NRI; risk groups were defined according
to estimated mortality risks of7%, 7% to 15%, and15%.
hese categories were pre-specified on the basis of tertile
oundaries of the estimated risk for all-cause mortality with
light modification to obtain a reasonable number of cases in
ach category. The Hosmer-Lemeshow test comparing
m
iobserved and predicted event rates was used to assess the
goodness-of-fit of the applied models.
In all tests, a 2-sided p value 0.05 was considered
significant. SPSS version 19.0 (IBM SPSS Statistics, IBM
Corporation, Armonk, New York) and Stata version 11.0
(Stata Corp., College Station, Texas) were used for the
statistical analyses.
Results
Baseline cTnI levels and their relations to clinical
characteristics. Results for cTnI at baseline were avail-
able in 1,004 study participants. cTnI levels ranged from
0.7 to 1,293.7 ng/l with a median of 3.4 ng/l (25th, to
75th percentiles: 2.5 to 5.1 ng/l). In total, 968 subjects
(96.4%) had cTnI levels greater than or equal to the limit
of detection of 1.5 ng/l. The distribution of baseline cTnI
levels is illustrated in the Supplemental Figure 1, and the
clinical characteristics of the study population are given
in Table 1.
By multiple linear regression using baseline cTnI (ln) as a
dependent variable, independent and consistent associations
existed between cTnI and male sex (p  0.001), hyperten-
sion (p 0.03), ischemic electrocardiographic changes (p
Clinical Characteristics of theStudy Population (N  1,004)Table 1 Clinical Charact ristics of theStudy Population (N  1,004)
Male 502 (50.0)
Hypertension 726 (72.3)
Systolic BP (mm Hg) 150 23
Diastolic BP (mm Hg) 79 10
Diabetes 115 (11.5)
Body mass index (kg/m2) 27.0 4.3
Current smoking 107 (10.7)
Previous smoking 414 (41.2)
Ischemic ECG changes 171 (17.0)
History
Myocardial infarction 66 (6.6)
Heart failure 35 (3.5)
PCI/CABG 53 (5.3)
Stroke 34 (3.4)
Biochemistry
Glucose (mmol/l) 5.3 1.6
HDL cholesterol (mmol/l) 1.5 0.4
LDL cholesterol (mmol/l) 3.4 0.9
Triglycerides (mmol/l) 1.3 0.6
NT-proBNP (ng/l) 111 (65–183)
CRP (mg/l) 1.2 (0.6–2.3)
eGFR (ml/min/1.73 m2) 79.0 (65.5–94.4)
Echocardiographic data
LVEF (%)* 66.6 8.0
LVMI (g/m2)* 92.9 26.8
Values are frequencies (%), median (25th to 75th percentile), or mean  SD. *n  827.
BP  blood pressure; CABG  coronary artery bypass graft; CRP  C-reactive protein; ECG 
lectrocardiography; eGFR  estimated glomerular filtration rate; HDL  high-density lipoprotein;
DL  low-density lipoprotein; LVEF  left ventricular ejection fraction; LVMI  left ventricular
ass index; NT-proBNP N-terminal pro–B-type natriuretic peptide; PCI percutaneous coronary
ntervention.
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C-reactive protein (p  0.03), lower LVEF (p  0.01), and
higher LVMI (p  0.001). The body mass index was
associated with cTnI (ln) in an analysis excluding echocar-
diographic variables but not the eGFR (ln) or other meta-
bolic parameters (Online Table 1).
The change of cTnI levels over time and its predictors. Re-
sults for cTnI at both baseline and 5-year follow-up (5.1 
0.1 years from the baseline examinations) were available in
814 subjects. None of these subjects had experienced an
intercurrent cardiovascular event within the 28 days preced-
ing the follow-up visit. Considering baseline characteristics,
participants in the follow-up examinations tended to be
somewhat healthier compared with those not participating,
particularly in terms of lower prevalences of diabetes and
current smoking, a lower LVMI, and lower levels of
NT-proBNP (Online Table 2).
cTnI levels at baseline and 5-year follow-up were strongly
correlated (r 0.73; p 0.001). Median levels increased by
45%, from 3.4 (2.5 to 4.9) ng/l at baseline to 4.9 (3.6 to 7.0)
ng/l at 5-year follow-up (p  0.001). Accordingly, the
number of subjects with detectable cTnI levels increased
from 782 (96.1%) to 808 (99.3%).
By multiple linear regression using the change of cTnI
levels as a dependent variable, male sex, lower HDL
cholesterol, higher NT-proBNP levels, and lower LVEF
were independently and consistently associated with
changes (Table 2). A history of myocardial infarction and a
higher body mass index revealed significant associations in
Multiple Linear Regression: Predictors of the Change in cTnI LevelsTable 2 Multiple Linear Regression: Predictors of the Change i
Clinical Variables
Model 1 (n  814)
Beta p Value
Male 0.119 0.001
Hypertension 0.005 0.88
Diabetes 0.084 0.01
Body mass index 0.109 0.001
HDL cholesterol 0.163 0.001
LDL cholesterol 0.093 0.004
Current smoking 0.021 0.52
Previous smoking 0.025 0.45
Ischemic ECG 0.050 0.14
Previous MI 0.090 0.006
Heart failure 0.046 0.15
Previous PCI/CABG 0.068 0.04
Previous stroke 0.045 0.16
NT-proBNP (ln) 0.009 0.007
CRP (ln) 0.032 0.33
eGFR (ln) 0.046 0.15
LVEF* 0.119 0.001
LVMI* 0.124 0.001
Intercurrent CV events 0.084 0.01
Model 1: adjusted for ln-transformed cardiac troponin I (cTnI) levels at baseline. Model 2: adjusted
cTnI at a p value  0.01 and excluding echocardiographic variables. Model 3: adjusted for cTnI (ln
T-proBNP (ln). *Assessed in model 1 in the 827 subjects with complete echocardiographic exam
BP  blood pressure; CABG  coronary artery bypass graft; CRP  C-reactive protein; ECG  electroc
low-density lipoprotein; LVEF  left ventricular ejection fraction; LVMI  left ventricular mass index; NT-panalyses with and without adjustment for echocardiographic
variables, respectively. Extending model 2 of the multiple
linear regressions with biomarker results obtained at the
5-year follow-up (n  802), the changes in NT-proBNP,
and the eGFR from 70 to 75 years of age emerged as entities
significantly associated with the change in cTnI levels
(change in NT-proBNP: beta  0.229, p  0.001; change
n eGFR: beta  0.068, p  0.03). The change in
-reactive protein levels from 70 to 75 years was not
ssociated with changes in cTnI (data not shown). Initiation
f lipid-lowering medication (n  99 [12.1%]), antihyper-
ensive medication (n  248 [30.4%]), and coronary revas-
ularization (n  34 [4.2%]) after baseline were not asso-
iated with cTnI changes when forced as additional
ovariates into model 2 (data not shown).
ortality in relation to cTnI levels. During the total
ollow-up period (median: 8.0 [7.1 to 8.9] years), 111
ubjects (11.0%) died. Cardiovascular death occurred in 37
ubjects (3.7%). The shape of the relationship between
aseline cTnI levels and all-cause mortality is illustrated in
igure 1. Because a linear relationship was found, we used
TnI (ln) as a continuous variable in the following survival
nalyses.
According to Cox regression analysis using cTnI (ln)
evels at both 70 and 75 years in an updated covariate
ashion and adjusting for established cardiovascular risk
ndicators, cTnI was a strong predictor of all-cause mortal-
ty, with a hazard ratio (HR) of 1.44 for a 1-unit increase in
n-transformed cTnI levels (95% confidence interval [CI]:
Baseline to 5-Year Follow-UpI Levels From Baseline to 5-Year Follow-Up
Model 2 (n  814) Model 3 (n  682)
Beta p Value Beta p Value
0.088 0.02 0.80 0.04
— — — —
0.034 0.30 0.018 0.61
0.085 0.01 0.039 0.29
0.100 0.005 0.092 0.02
0.054 0.10 0.026 0.46
— — — —
— — — —
— — — —
0.027 0.48 0.104 0.02
— — — —
0.012 0.75 0.053 0.21
— — — —
0.100 0.004 — —
— — — —
— — — —
— — 0.076 0.04
— — 0.050 0.20
0.044 0.29 0.076 0.12
nI (ln) at baseline and candidate covariates from model 1 with an association with the change of
eline and candidate covariates from model 1 including echocardiographic indexes and excluding
s at baseline.Fromn cTn
for cT
) at bas
inationardiography; eGFR  estimated glomerular filtration rate; HDL  high-density lipoprotein; LDL 
roBNP  N-terminal pro–B-type natriuretic peptide; PCI  percutaneous coronary intervention.
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for NT-proBNP (ln) did not affect this association (HR:
1.36 [95% CI: 1.09 to 1.70]; p  0.006). Similar findings
merged after additional adjustment for LVEF and LVMI
HR: 1.41 [95% CI: 1.12 to 1.77]; p  0.003). Adjusting
or established cardiovascular risk indicators, the HR of
TnI (ln) regarding cardiovascular death was 1.66 (95% CI:
.20 to 2.29; p  0.002). Even in secondary analyses
djusting for the Framingham risk score and using cTnI
evels from both measurement instances as updated covari-
tes, cTnI (ln) was strongly associated with all-cause mor-
ality (HR: 1.50 [95% CI: 1.24 to 1.82]; p  0.001) and
ardiovascular mortality (HR: 1.63 [95% CI: 1.19 to 2.24];
 0.002).
Table 4 demonstrates that baseline cTnI levels improved
rognostic discrimination and reclassification. Both the IDI
nd the category-free NRI were significant regardless of
Cox Proportional Hazards Regression Model Evaluating the Risk ofBaseline and 5-Year Follow-Up a Update Co riates and AdjustinTable 3 Cox Prop rtional H zards R gression Model EvaluatingBaseline and 5-Year Follow-Up as Updated Covariates
Clinical Variables
All-Cause Mortality (n  1,79
HR (95% CI)
cTnI (ln) 1.44 (1.18–1.77)
Male 1.17 (0.72–1.46)
Hypertension 0.72 (0.48–1.11)
Diabetes 1.69 (1.01–2.80)
Body mass index 0.96 (0.91–1.00)
HDL cholesterol 0.95 (0.57–1.58)
LDL cholesterol 0.91 (0.72–1.15)
Current smoking 2.03 (1.24–3.32)
CRP (ln) 1.13 (0.95–1.36)
eGFR (ln) 0.68 (0.32–1.43)
Previous CV disease 1.50 (0.90–2.50)
Figure 1 cTnI Levels (ln) in Relation
to All-Cause Mortality Risk
Shape of the relationship between baseline cardiac troponin I (cTnI) levels (ln)
and all-cause mortality. The curve of average risk was derived from general
additive models.CI  confidence interval; HR  hazard ratio; other abbreviations as in Tables 1 and 2.hether cTnI was added to a model based on cardiovascular
isk indicators or the Framingham risk score. In addition, a
ood model-fit was seen after addition of cTnI to both
odels (Hosmer-Lemeshow test, p  0.11). The changes
n the C-statistic, in contrast, were nonsignificant, and the
ategory-based NRI only approached levels of significance.
he incremental value of baseline cTnI levels was abrogated
hen NT-proBNP (ln) was added to the model based on
ardiovascular risk indicators (IDI: 0.120 [p  0.07];
ategory-free NRI: 0.140 [p  0.17].
ll-cause mortality in relation to the change in cTnI
evels. Among the 814 subjects with available cTnI results at
oth 70 and 75 years of age, 32 deaths (3.9%) occurred
etween the 5-year follow-up examinations and the censor
ate at the end of December 2010 (median: 2.9 [2.1 to 3.8]
ears). Because only 12 deaths were due to cardiovascular
auses, we focused on all-cause mortality in this part of the
nalysis.
Applied as continuous variable, the change in cTnI levels
as significantly predictive of all-cause mortality occurring
fter the 5-year follow-up examinations. Subjects with the
ost pronounced increases in cTnI levels (i.e., changes in
he highest quartile) had a doubled all-cause mortality
ompared with those with changes in the lowest 3 quartiles
adjusted HR: 2.20 [95% CI: 1.05 to 4.64]; p 0.04) (Fig. 2).
djusting for established cardiovascular risk indicators,
aseline cTnI (ln), and intercurrent cardiovascular events,
he HR of the change in cTnI levels was 1.97 (95% CI: 1.14
o 3.40; p  0.02) (Table 5). The change in cTnI levels
emained predictive after additional adjustment for NT-
roBNP (ln) with an HR of 1.91 (95% CI: 1.09 to 3.33;
 0.02). Even after adjustment for the Framingham risk
core, the change in cTnI levels was significantly associated
ith all-cause mortality (HR: 1.98 [95% CI: 1.16 to 3.38];
 0.01). However, the change in cTnI levels did not
mprove any of the tested metrics of prognostic discrimina-
ion or reclassification (data not shown).
ality by Using cTnI (ln) Levels FromEs ablished Cardiovascular Risk IndicatorsRisk of Mortality by Using cTnI (l ) Levels From
djusting for Established Cardiovascular Risk Indicators
Cardiovascular Mortality (n  1,782)
lue HR (95% CI) p Value
001 1.66 (1.20–2.29) 0.002
41 1.13 (0.87–1.60) 0.73
14 1.27 (0.60–2.70) 0.53
04 1.15 (0.45–2.93) 0.77
07 0.90 (0.82–0.99) 0.03
84 0.64 (0.25–1.62) 0.35
43 0.98 (0.66–1.46) 0.92
005 2.52 (1.00–6.33) 0.05
18 0.88 (0.64–1.21) 0.44
31 0.55 (0.19–1.58) 0.27
12 1.73 (0.72–4.14) 0.22Mortg fthe
and A
7)
p Va
0.
0.
0.
0.
0.
0.
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In this analysis using the novel ARCHITECT STAT hsTnI
assay, we were for the first time able to quantify cTnI levels
in almost all subjects from a fairly large cohort of elderly
community dwellers. This method enabled us to assess the
implications of cTnI across the range of all concentrations,
and we found that cTnI, together with its changes over
time, was a strong predictor of mortality. Our findings
suggest that repetitive measurements of cTnI levels using a
high-sensitive assay might serve as a valuable adjunct for
clinical assessment when added to conventional estimates of
cardiovascular risk.
Similar to investigations assessing troponin T in general
populations, cTnI levels in the present analysis were inde-
pendently related to cardiovascular risk factors (i.e., male
sex, hypertension), indicators of coronary artery disease (i.e.,
ischemic electrocardiographic changes), low-grade inflam-
mation (i.e., C-reactive protein levels), and left ventricular
abnormalities (i.e., NT-proBNP levels and echocardio-
graphic findings) (2–4). Corresponding to the notion that
cTnI reflects chronic processes adversely affecting cardio-
myocyte integrity, it was also found to be a powerful
predictor of both all-cause mortality and cardiovascular
Figure 2
Cumulative Incidence of All-Cause
Mortality After 5-Year Follow-Up in Relation to
the Change in cTnI Levels During the First 5 Years
Cardiac troponin I (cTnI) changes are categorized by quartiles of the absolute
change in cTnI (ln) between baseline and 5-year follow-up. Adjustment was
made for baseline cTnI (ln), sex, and the estimated glomerular filtration rate.
CI  confidence interval; HR  hazard ratio.
Incremental Value of Baseline cTnI Levels Regarding the PredictionTable 4 Incremental Value of Baseline cTnI Levels Regarding t
Risk Model
Increase in
C-Statistic p Value IDI
CV risk indicators 0.003 0.51 0.014
CV risk indicators  NT-proBNP (ln) 0.006 0.60 0.120
Framingham risk score 0.040 0.17 0.017
IDI  integrated discrimination improvement; NRI  net reclassification improvement; other abbmortality. cTnI provided prognostic value independent of
established cardiovascular risk indicators or the Framing-
ham risk score, emerged as a strong risk predictor in a model
using levels obtained at 70 and 75 years of age as updated
covariates, and yielded incremental prognostic value in
terms of improved discrimination and reclassification.
We found a linear shape of the association between cTnI
levels and mortality risk, starting at the already very low
cTnI concentrations. This is a novel finding and extends
data from studies using the high-sensitive cardiac troponin
T assay in which levels had been undetectable in at least
35% of the assessed populations (2–5). Even though very
low troponin levels have been ascribed to physiologic
processes such as cardiomyocyte turnover or reversible
cardiomyocyte damage with troponin leakage from the
cytosolic pool (18), our data indicate that they also, to some
extent, carry information on prognostic adverse processes
affecting the myocardium.
cTnI levels increased significantly during the first 5 years
of the follow-up period (i.e., from 70 to 75 years of age). In
particular, males and subjects with indicators of chronic
cardiac abnormalities (i.e., a history of myocardial infarc-
tion, lower LVEF, higher levels of NT-proBNP) were most
likely to have increasing cTnI levels. This finding points
toward progressive myocardial impairment as the underly-
ing cause. Even lower HDL cholesterol and a higher body
mass index emerged as independent predictors of cTnI
changes, which might reflect the role of these entities on the
ll-Cause Mortalityediction of All-Cause Mortality
e Category-Based NRI p Value Category-Free NRI p Value
0.084 0.05 0.231 0.02
0.036 0.40 0.140 0.17
0.086 0.06 0.288 0.004
ns as in Tables 1 and 2.
Cox Proportional Hazards RegressionAnalysis Evaluating the Risk of All-CauseMortal ty Associated With the Changein cTnI Levels in a Model Adjusted forEstabli hed CV Risk In ica ors (n  806)
Table 5
Cox Proportional Hazards Regression
Analysis Evaluating the Risk of All-Cause
Mortality Associated With the Change
in cTnI Levels in a Model Adjusted for
Established CV Risk Indicators (n  806)
Variable HR (95% CI) p Value
Change in cTnI (ln) 1.97 (1.14–3.40) 0.02
Male 1.03 (0.44–2.42) 0.94
Hypertension 1.07 (0.45–2.56) 0.87
Diabetes 2.28 (0.92–5.68) 0.08
Body mass index 0.69 (0.39–1.22) 0.20
HDL cholesterol 0.61 (0.21–1.75) 0.36
LDL cholesterol 1.14 (0.74–1.74) 0.56
Current smoking 1.31 (0.44–3.88) 0.63
CRP (ln) 0.85 (0.58–1.27) 0.43
eGFR (ln) 1.99 (0.42–9.35) 0.39
Previous CV disease 0.71 (0.19–2.63) 0.61
Intercurrent CV events 1.56 (0.50–4.84) 0.45of Ahe Pr
p Valu
0.04
0.07
0.01Abbreviations as in Tables 1, 2, and 3.
d
t
l
fi
a
o
m
t
v
s
c
i
h
u
1912 Eggers et al. JACC Vol. 61, No. 18, 2013
Cardiac Troponin in Subjects From the Community May 7, 2013:1906–13development of coronary atherosclerosis, leading to chronic
myocardial ischemia with troponin leakage. Troponin levels
may be elevated in subjects with stable coronary artery
disease (19,20) and have been shown in some (21),
although not all (2), studies to be associated with the
egree of coronary atherosclerosis, which lends support
o this hypothesis.
Although the association of cTnI levels with obesity and
ipid abnormalities seen in our cohort is consistent with
ndings from previous investigations (2–4,19), we found no
ssociation with hyperglycemia or diabetes, as reported from
ther studies (5,22). Diabetes may result in subclinical
yocardial injury through various mechanisms (e.g., oxida-
ive stress, enhanced myocardial fibrosis, coronary micro-
ascular dysfunction, macrovascular atherosclerosis) (22).
We do not regard the absence of an association between
diabetes and cTnI levels in our analysis as an argument
against these mechanisms; it may be explained by the
relative low prevalence of diabetes among our study partic-
ipants and the fact that we lack data on more sensitive
estimates of hyperglycemia (e.g., glycosylated hemoglobin).
The change in cTnI levels over time was independently
associated with a higher risk of all-cause mortality, which
corresponds to data from the CHS (Cardiovascular Health
Study) using high-sensitive troponin T (3). Similar to that
study, we found that subjects with the most pronounced
increase (i.e., those with changes in the highest quartile) had
a doubled mortality risk despite the rather short observation
period. However, the change in cTnI levels provided only
limited incremental value to established cardiovascular risk
indicators or the Framingham risk score. Although repeat
measurements of cTnI seem to be helpful for the iden-
tification of higher risk subjects, the role of this measure
for clinical decision making therefore remains to be
determined.
Several other issues need to be considered with respect to
the potential clinical application of cTnI measurement in
general populations. First, appropriate decision limits need
to be defined, both with respect to assay performance,
distribution characteristics, and the biological long-term
variation of troponin levels, considering that cTnI levels far
below commonly used thresholds (e.g., the 99th percentile)
seemed to be of prognostic relevance in our study. Second,
the myocardial processes resulting in troponin leakage
might be potentially modifiable by directed health care
interventions. It is therefore tempting to speculate that
changes in cTnI levels could serve as a surrogate marker
reflecting cardioprotective effects of lifestyle or medical
interventions, but this assumption needs to be tested in
future randomized clinical trials.
Study limitations. The PIVUS study was limited to white
ubjects aged 70 years. We are therefore reluctant to draw
onclusions to other ethnic or age groups. The participants
n the 5-year follow-up examinations represent a somewhat
ealthier subset of the entire study population, which is
navoidable in longitudinal studies assessing elderly popu-lations. Results obtained from this cohort can therefore not
be extrapolated to the entire study population but likely
underestimate the true associations between cTnI levels and
outcome. cTnI results were entered into the analyses as
given, even for the few subjects with results below the limit
of detection of the applied assay. Assigning a value of 1.2
ng/l (i.e., a value between the limit of blank and the limit of
detection) for undetectable levels did not alter any of the
results of our analysis (data not shown). We evaluated
changes in cTnI levels on a continuous scale and not by
categories (e.g., increasing or decreasing). This method was
based on the fact that only 16 study participants had a
decrease by more than 50%, an estimate that presumably
distinguishes true decreases from fluctuations in cTnI levels
due to their biological variability. Finally, we cannot exclude
the possibility that our modeling approach might have
affected the prognostic estimates of cTnI given the some-
what low event rate for some outcomes.
Conclusions
Our data demonstrated that cTnI levels could be measured
in almost all these elderly study subjects when using a
high-sensitive assay. cTnI levels and their changes over time
were not only related to indicators of cardiovascular risk but,
more importantly, emerged as powerful and independent
predictors of both all-cause mortality and cardiovascular
mortality. The challenge for future research will be to define
the clinical utility of cTnI determinations in primary pre-
vention strategies and to determine if cTnI could be used to
monitor the beneficial effects of cardioprotective therapies.
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